In yesterday’s Wall Street session, Taysha Gene Therapies Inc. (NASDAQ:TSHA) shares traded at $2.18, up 2.35% from the previous session.
9 analysts cover Taysha Gene Therapies Inc. (NASDAQ:TSHA), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $8.00 and a low of $2.00, we find $6.00. Given the previous closing price of $2.13, this indicates a potential upside of 181.69 percent. TSHA stock price is now 196.26% away from the 50-day moving average and 78.47% away from the 200-day moving average. The market capitalization of the company currently stands at $133.05M.
The stock has received a hold rating from 1 analysts and a buy rating from 7. Brokers who have rated the stock have averaged $5.72 as their price target over the next twelve months.
With the price target reduced from $14 to $1.50, Jefferies Downgraded its rating from Buy to Hold for Taysha Gene Therapies Inc. (NASDAQ: TSHA).
In other news, Session R.A. II, 10% Owner sold 5,344 shares of the company’s stock on Jul 13. The stock was sold for $3,741 at an average price of $0.70. Upon completion of the transaction, the 10% Owner now directly owns 8,871,747 shares in the company, valued at $19.34 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 12, 10% Owner Session R.A. II sold 80,528 shares of the business’s stock. A total of $57,030 was realized by selling the stock at an average price of $0.71. This leaves the insider owning 8,877,091 shares of the company worth $19.35 million. Insiders disposed of 466,615 shares of company stock worth roughly $1.02 million over the past 1 year. A total of 3.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TSHA stock. A new stake in Taysha Gene Therapies Inc. shares was purchased by SQUAREPOINT OPS LLC during the first quarter worth $176,000. DYNAMIC ADVISOR SOLUTIONS LLC invested $98,000 in shares of TSHA during the first quarter. In total, there are 61 active investors with 23.20% ownership of the company’s stock.
On Tuesday morning Taysha Gene Therapies Inc. (NASDAQ: TSHA) stock kicked off with the opening price of $2.2600. During the past 12 months, Taysha Gene Therapies Inc. has had a low of $0.50 and a high of $4.63. The fifty day moving average price for TSHA is $0.7637 and a two-hundred day moving average price translates $1.2216 for the stock.
The latest earnings results from Taysha Gene Therapies Inc. (NASDAQ: TSHA) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.38, missing analysts’ expectations of -$0.31 by -0.07. This compares to -$0.85 EPS in the same period last year. For the current quarter, analysts expect TSHA to generate $1.32M in revenue.
Taysha Gene Therapies Inc.(TSHA) Company Profile
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
